EB-003 — Safety, Research, Risks & Legal Status

Q: What makes EB-003 different from classical psychedelics like psilocybin?

The core design distinction is the non-hallucinogenic profile. Classical psychedelics such as psilocybin produce hallucinogenic effects primarily through potent 5-HT2A full agonism. EB-003 is engineered as a partial agonist at 5-HT2A with specific signaling bias, and it additionally targets 5-HT1B and 5-HT1A, while deliberately avoiding 5-HT2B activation. The developer's hypothesis is that this receptor profile promotes neuroplastic rewiring without the perceptual effects. Whether this distinction holds in humans has not yet been tested.

Q: Has EB-003 been tested in humans?

No. As of mid-2026, all data for EB-003 are from preclinical animal studies and in vitro receptor assays. No Phase 1 human trial has been registered or completed. IND submission to the FDA was planned for early 2026, and first-in-human studies are anticipated but have not yet occurred.

Q: What condition is EB-003 being developed for?

PTSD is the primary indication suggested by the available preclinical work, specifically a mouse conditioned fear model. Enveric Biosciences frames EB-003 more broadly as a neuroplastogen for neuropsychiatric conditions, but PTSD-related evidence is what has been publicly disclosed. No efficacy has been established in any human condition.

Q: Can I participate in or access an EB-003 clinical trial?

As of mid-2026, no EB-003 clinical trial has been registered on ClinicalTrials.gov. Phase 1 trials are anticipated once IND authorization is granted. Monitoring ClinicalTrials.gov (search 'EB-003' or 'Enveric Biosciences') is the appropriate way to track enrollment opportunities.

Q: What is the evidence quality for EB-003?

Very limited and early-stage. Available data originate almost entirely from company press releases and proprietary data on file, not peer-reviewed independent publications. The preclinical PTSD mouse model result is a single data point from a single company report. BRET assay mechanistic data are similarly company-generated. This compound should be regarded as hypothesis-generating at best until independent peer-reviewed and clinical data emerge.

Q: Where can I get dosing guidance for EB-003?

No dosing guidance exists for human use. Animal model dosing cannot be translated to humans without Phase 1 pharmacokinetic studies, which have not been conducted. Any source claiming to offer EB-003 dosing protocols is not based on clinical evidence. A licensed clinician and the official clinical trial protocol, once available, are the only appropriate resources.

Not medical advice. EB-003 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	EB-003 (Enveric Biosciences development code); "neurostabilogen" (developer-coined term)
Category	Research Chemical
Developer	Enveric Biosciences (NASDAQ: ENVB), a public biotech focused on neuroplastogen development for neuropsychiatric conditions
Drug class	Non-hallucinogenic neuroplastogen; tryptamine derivative; dual serotonergic engager
Primary targets	5-HT2A (partial agonist, Gq and beta-arrestin), 5-HT1B (agonist), 5-HT1A (agonist); does not activate 5-HT2B
Development stage (mid-2026)	Preclinical / pre-IND; IND submission planned early 2026 after positive FDA pre-IND Type B response (September 2025)
Key preclinical signal	Single-dose reduction in context-induced freezing in mouse PTSD model (p<0.05, May 2026 data)
Human trials	None conducted or registered as of mid-2026; Phase 1 anticipated pending IND clearance
US legal status	Unapproved investigational compound in the United States. EB-003 has no FDA-approved indication and is not legally available outside of a clinical trial context. Its scheduling status has not been formally assigned; as a novel tryptamine derivative it may be subject to analogue provisions depending on final structure disclosure. An IND submission to FDA was planned for early 2026 following a positive pre-IND Type B meeting response (September 2025) in which FDA identified no major barriers to proceeding. Not for human consumption outside of authorized clinical research.

What is EB-003?

EB-003 is an investigational tryptamine derivative and neuroplastogen under development by Enveric Biosciences (NASDAQ: ENVB) for potential neuropsychiatric indications, most notably PTSD. The compound is designed to produce adaptive neuroplastic effects through serotonin receptor engagement while deliberately avoiding the hallucinogenic properties associated with classical psychedelics such as psilocybin or LSD. Its exact chemical structure has not been publicly disclosed and is covered by patent filings. All data as of mid-2026 remain preclinical or mechanistic; no human studies have been conducted.

How it works

EB-003 is characterized by Enveric Biosciences as a dual serotonergic engager. Mechanistic profiling using BRET (bioluminescence resonance energy transfer) receptor engagement assays (data reported February 2026) indicates partial agonism at the 5-HT2A receptor via both Gq protein-mediated and beta-arrestin-mediated signaling pathways. It also engages the 5-HT1B receptor as an agonist and the 5-HT1A receptor. Notably, the compound is reported not to activate the 5-HT2B receptor, which is associated with cardiac valvulopathy risk in other serotonergic agents. The mechanistic hypothesis is that 5-HT2A engagement promotes neuroplastic rewiring (synaptogenesis, dendritic remodeling) while the absence of sufficient hallucinogenic signaling bias - or the combination of receptor targets - prevents the perceptual and dissociative effects seen with classical psychedelics. This hypothesis has not yet been tested or confirmed in human subjects.

Background & history

Enveric Biosciences, a public biotech company focused on neuroplastogen development, publicly disclosed EB-003 as its lead pipeline compound targeting neuropsychiatric conditions. In September 2025, Enveric announced that FDA had responded to a pre-IND Type B meeting request and directed the company to proceed directly to IND application, indicating no major regulatory barriers at that stage. BRET assay mechanistic data were reported in February 2026. Positive preclinical efficacy results in a mouse PTSD model (context-induced fear conditioning) were highlighted by the company in May 2026. As of mid-2026, the compound remains pre-IND or early-IND stage with first-in-human Phase 1 trials anticipated but not yet registered.

What the research says

All available evidence is preclinical and mechanistic as of mid-2026. In a validated conditioned fear mouse model used as a PTSD surrogate, a single dose of EB-003 was reported to significantly reduce context-induced freezing behavior within one hour post-administration (p less than 0.05; data highlighted May 2026). BRET assay data published February 2026 confirmed dual Gq and beta-arrestin engagement at 5-HT2A. No peer-reviewed, independently replicated publications describing EB-003 specifically have been identified in the literature; available data originate from company press releases and proprietary data on file. No human pharmacokinetic, pharmacodynamic, safety, or efficacy data exist. The compound has not been registered on ClinicalTrials.gov as of mid-2026. The evidence base should be considered very limited and primarily company-generated at this stage.

Reported effects

Preclinical only: reduced conditioned fear (context-induced freezing) in a mouse PTSD model following single dose administration
Hypothesized promotion of adaptive neuroplasticity (synaptogenesis, dendritic remodeling) via 5-HT2A engagement - not yet demonstrated in humans
Non-hallucinogenic profile claimed based on receptor selectivity design - not confirmed in human trials
No confirmed human effects; all effect claims are extrapolated from animal models or mechanistic in vitro assays
Serotonin receptor engagement across 5-HT2A, 5-HT1B, and 5-HT1A subtypes documented by BRET assay data

Dosing & administration (informational)

No dosing information for human use exists. Preclinical mouse model data describe single-dose administration, but animal-to-human dose translation has not been established or published. Dosing will be defined by the Phase 1 clinical trial protocol once IND authorization is granted. This entry does not provide, suggest, or imply any dosing guidance. Consult a licensed clinician and refer to official clinical trial protocols for any investigational use questions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety profile is entirely uncharacterized; no clinical trial data exist
No adverse events have been reported in published preclinical summaries, but formal toxicology disclosure is limited
Non-hallucinogenic design is intended to reduce psychedelic-related risks such as acute psychological distress, but this has not been confirmed in humans
Absence of 5-HT2B agonism is a favorable design feature for cardiac safety, but formal cardiovascular toxicology has not been publicly disclosed
Serotonin syndrome risk, drug-drug interactions, and contraindication profile are unknown pending Phase 1 human data
Preclinical safety data from IND-enabling studies have not been made public
As a tryptamine derivative with serotonergic activity, theoretical risks of serotonergic excess exist, particularly in combination with other serotonergic agents

Drug & supplement interactions

U
n
k
n
o
w
n
.
N
o
h
u
m
a
n
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
o
r
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
c
o
n
d
u
c
t
e
d
o
r
p
u
b
l
i
s
h
e
d
.
B
a
s
e
d
o
n
t
h
e
s
e
r
o
t
o
n
e
r
g
i
c
m
e
c
h
a
n
i
s
m
(
5
-
H
T
2
A
,
5
-
H
T
1
B
,
5
-
H
T
1
A
a
g
o
n
i
s
m
)
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
o
t
h
e
r
s
e
r
o
t
o
n
e
r
g
i
c
c
o
m
p
o
u
n
d
s
-
i
n
c
l
u
d
i
n
g
S
S
R
I
s
,
S
N
R
I
s
,
M
A
O
I
s
,
t
r
i
p
t
a
n
s
,
a
n
d
o
t
h
e
r
s
e
r
o
t
o
n
i
n
r
e
c
e
p
t
o
r
l
i
g
a
n
d
s
-
a
r
e
p
l
a
u
s
i
b
l
e
a
n
d
h
a
v
e
n
o
t
b
e
e
n
f
o
r
m
a
l
l
y
e
v
a
l
u
a
t
e
d
.
C
o
a
d
m
i
n
i
s
t
r
a
t
i
o
n
w
i
t
h
a
n
y
s
e
r
o
t
o
n
e
r
g
i
c
a
g
e
n
t
s
h
o
u
l
d
b
e
c
o
n
s
i
d
e
r
e
d
a
p
o
t
e
n
t
i
a
l
r
i
s
k
p
e
n
d
i
n
g
c
l
i
n
i
c
a
l
d
a
t
a
.

Who should avoid it

Combining with any serotonergic agent (SSRIs, SNRIs, MAOIs, triptans, lithium) in the absence of clinical data - serotonin syndrome risk is theoretical but plausible
Use outside of authorized and IRB-approved clinical trials
Sourcing from unverified commercial vendors - authentic EB-003 is not commercially available and the structure is undisclosed
Use by individuals with personal or family history of psychosis, mania, or serotonin-related disorders absent formal clinical evaluation
Use during pregnancy or lactation - no reproductive or developmental toxicology data exist

How it is commonly combined

No stacking data exist. The compound has never been studied in humans and has not been evaluated in combination with any other agent in published research. Combination use is not assessable from available evidence and would carry unknown risks.

Legal & regulatory. Unapproved investigational compound in the United States. EB-003 has no FDA-approved indication and is not legally available outside of a clinical trial context. Its scheduling status has not been formally assigned; as a novel tryptamine derivative it may be subject to analogue provisions depending on final structure disclosure. An IND submission to FDA was planned for early 2026 following a positive pre-IND Type B meeting response (September 2025) in which FDA identified no major barriers to proceeding. Not for human consumption outside of authorized clinical research.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find EB-003 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes EB-003 different from classical psychedelics like psilocybin?

The core design distinction is the non-hallucinogenic profile. Classical psychedelics such as psilocybin produce hallucinogenic effects primarily through potent 5-HT2A full agonism. EB-003 is engineered as a partial agonist at 5-HT2A with specific signaling bias, and it additionally targets 5-HT1B and 5-HT1A, while deliberately avoiding 5-HT2B activation. The developer's hypothesis is that this receptor profile promotes neuroplastic rewiring without the perceptual effects. Whether this distinction holds in humans has not yet been tested.

Has EB-003 been tested in humans?

No. As of mid-2026, all data for EB-003 are from preclinical animal studies and in vitro receptor assays. No Phase 1 human trial has been registered or completed. IND submission to the FDA was planned for early 2026, and first-in-human studies are anticipated but have not yet occurred.

What condition is EB-003 being developed for?

PTSD is the primary indication suggested by the available preclinical work, specifically a mouse conditioned fear model. Enveric Biosciences frames EB-003 more broadly as a neuroplastogen for neuropsychiatric conditions, but PTSD-related evidence is what has been publicly disclosed. No efficacy has been established in any human condition.

Can I participate in or access an EB-003 clinical trial?

As of mid-2026, no EB-003 clinical trial has been registered on ClinicalTrials.gov. Phase 1 trials are anticipated once IND authorization is granted. Monitoring ClinicalTrials.gov (search 'EB-003' or 'Enveric Biosciences') is the appropriate way to track enrollment opportunities.

What is the evidence quality for EB-003?

Very limited and early-stage. Available data originate almost entirely from company press releases and proprietary data on file, not peer-reviewed independent publications. The preclinical PTSD mouse model result is a single data point from a single company report. BRET assay mechanistic data are similarly company-generated. This compound should be regarded as hypothesis-generating at best until independent peer-reviewed and clinical data emerge.

Where can I get dosing guidance for EB-003?

No dosing guidance exists for human use. Animal model dosing cannot be translated to humans without Phase 1 pharmacokinetic studies, which have not been conducted. Any source claiming to offer EB-003 dosing protocols is not based on clinical evidence. A licensed clinician and the official clinical trial protocol, once available, are the only appropriate resources.

References & further reading

PubMed: Enveric Biosciences neuroplastogen serotonin receptor
PubMed: EB-003 5-HT2A neuroplasticity PTSD
ClinicalTrials.gov: search 'EB-003' and 'Enveric Biosciences' (no trials registered as of mid-2026; monitor for Phase 1 IND-enabled registration)
Enveric Biosciences newsroom (enveric.com): press releases February 2026 (BRET assay data), May 2026 (PTSD preclinical results), September 2025 (FDA pre-IND response)
PubMed: neuroplastogen non-hallucinogenic psychoplastogen 5-HT2A neuropsychiatric